Status:
COMPLETED
Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40-100 years
Brief Summary
Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or all-cause mortality in Chronic Obstructive Pulmonary Disease (COPD) patients who are new users of Olodaterol or...
Detailed Description
Purpose: Time Perspective:
Eligibility Criteria
Inclusion
- Inclusion criteria:
- COPD diagnosis
- aged 40 years or older (to minimise the likelihood of including individuals who have asthma only)
- New user of olodaterol or a new user of indacaterol, salmeterol, or formoterol (not in fixed-dose combination with an inhaled corticosteroid) and have no dispensing of any LABA in the 6 months before the index date
- at least 1 year of enrolment in the electronic database before their first LABA dispensing (defined as the index LABA)
- Complete data on sex
- Exclusion criteria:
- none
Exclusion
Key Trial Info
Start Date :
January 31 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 3 2020
Estimated Enrollment :
65406 Patients enrolled
Trial Details
Trial ID
NCT03405363
Start Date
January 31 2018
End Date
February 3 2020
Last Update
April 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus Universitets hospital Skejby
Aarhus, Denmark